Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy - Wikidata - awgldk - TriplyDB

Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy

Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy

http://www.wikidata.org/entity/Q35118157

about

Raf-interactome in tuning the complexity and diversity of Raf function.Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma Conditional ablation of Ikkb inhibits melanoma tumor development in mice.Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis The NFκB pathway: a therapeutic target in glioblastoma.Antiproliferative Effect of Rottlerin on Sk-Mel-28 Melanoma Cells Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.

P2860

Q27692653-EBD54CFD-6271-4DB7-8A37-CF935CE55F68 Q28276026-B1A7402C-7D07-4461-8250-BA92B4A336C6 Q33968131-3BD51BB9-50F7-4645-924F-F224F7351B68 Q35230726-5894DB7D-CB76-43B1-9B78-824F2C4B87B4 Q37928304-5E1D47FF-D494-4521-B3BD-C04C1F561C9B Q38854630-12B59922-CB8B-43A1-AB66-29CFEF8D1818 Q39205142-E0FFC000-71BC-471E-9089-955143395C7B Q39686730-614976E0-E2F5-4597-8CC1-588920813E16 Q48218051-7F38EAE9-9AD6-45B1-B556-A3B929AFDC17

P2860

Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy

http://www.wikidata.org/entity/Q35118157

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Molecular determinants of mela ...... roved efficacy of chemotherapy

@ast

Molecular determinants of mela ...... roved efficacy of chemotherapy

@en

type

label

Molecular determinants of mela ...... roved efficacy of chemotherapy

@ast

Molecular determinants of mela ...... roved efficacy of chemotherapy

@en

prefLabel

Molecular determinants of mela ...... roved efficacy of chemotherapy

@ast

Molecular determinants of mela ...... roved efficacy of chemotherapy

@en

P1433

Q35118157-F80EC1DE-682E-4464-850A-D4BCFD3F5497

P1476

Q35118157-86C9F38F-ACA2-4E8B-AA89-803B9BEE6964

P2093

Q35118157-2730C2E9-FF8B-4A87-B473-789054AC6BFB

Q35118157-5170A13F-A5FE-4581-9BC5-2F6E0B089F02

Q35118157-84C68390-8CF7-42C6-A808-76CBA2EDE945

Q35118157-8E307F8F-A749-493D-B24B-E052F539483B

Q35118157-AD91028F-32AB-4F9C-9867-685F3CB7FC4B

Q35118157-ED031C88-BBB8-4DD2-8101-3E70835AD5D0

P2860

Q35118157-03EE1AA7-0F98-4E7B-B2D1-FEACD2CF4983

Q35118157-04B00C8B-FA0E-4039-B8FE-76DAB9ACE702

Q35118157-057600AD-37E5-4CEC-850F-CCE09CD58030

Q35118157-19692819-B558-4B82-9D67-C049B7A28F28

Q35118157-1982DF01-B463-442E-9CE6-E9F53E4A2FCC

Q35118157-19E4B5B5-9898-40A0-AE69-8A08737D8CD7

Q35118157-25E6CB27-A1D4-423A-8CFD-5375C38BA543

Q35118157-2F62FC8C-3F4A-4C6F-92F5-652D2B274AD8

Q35118157-2FA3AF1D-C4E3-48BF-9A5A-F301FA5FD605

Q35118157-303DE4AA-A996-4357-B85B-D87B18FEAC08

P304

Q35118157-08ACE96E-07EF-4884-BE4A-DBCEAA07F8FC

P31

Q35118157-EA66BCF1-669D-4CDB-A987-DA3A0E8B0CA5

P356

Q35118157-87F6BD37-C67E-4486-A67D-DFDA0F2358EE

P433

Q35118157-A8CC4242-009B-4830-B7BB-BA152DD1DF34

P478

Q35118157-7A099726-C38E-4937-84C7-4ECB9E70C3BD

P577

Q35118157-E695148E-FCF2-43FF-90F3-FEB166B238D4

P5875

Q35118157-1851FB0E-CA0D-443B-AA7B-0E3254D4A18F

P698

Q35118157-1A66FF3B-CBB7-4110-A77E-44F8CD9274FC

P921

Q35118157-D82B8746-B8D3-4C88-8D27-B5B1B7BE0E6E

P932

Q35118157-0FEFC5FD-7A6A-4075-A586-D86CD2320399

P356

1535-7163.MCT-08-0749

P1433

Molecular Cancer Therapeutics

P1476

Molecular determinants of mela ...... roved efficacy of chemotherapy

@en

P2093

Ann Richmond

http://www.w3.org/2001/XMLSchema#string

Francis Lee

http://www.w3.org/2001/XMLSchema#string

Jinming Yang

http://www.w3.org/2001/XMLSchema#string

Richard Smykla

http://www.w3.org/2001/XMLSchema#string

Snjezana Zaja-Milatovic

http://www.w3.org/2001/XMLSchema#string

Yee-Mon Thu

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of the BRAF gene in human cancer

Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation

Determinants of BRAF mutations in primary melanomas

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Visualization of interactions among bZIP and Rel family proteins in living cells using bimolecular fluorescence complementation

p53: puzzle and paradigm

HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity.

Visualization of AP-1 NF-kappaB ternary complexes in living cells by using a BiFC-based FRET.

Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation.

The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation.

P304

636-647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-08-0749

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24191333

http://www.w3.org/2001/XMLSchema#string

P698

19276165

http://www.w3.org/2001/XMLSchema#string

P921

P932

3140401

http://www.w3.org/2001/XMLSchema#string